SCHEMBL20571237

SCHEMBL20571237

N#Cc1c(-c2nccs2)nc(-c2cccnc2)[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
HPGD P15428 6/20 0.52
ALDH1A1 P00352 5/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2A6 P11509 1/20 0.49
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ACMSD Q8TDX5 1/20 0.46
KDM4C Q9H3R0 1/20 0.44
HTT P42858 2/20 0.44
NPY5R Q15761 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 4/20 0.42
RXFP1 Q9HBX9 2/20 0.42
GAA P10253 2/20 0.42
PIM1 P11309 1/20 0.41
PPARG P37231 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20569842 0.91 HPGD (0.52) MAPTHPGDALDH1A1CYP1A2CYP2C9
SCHEMBL20570795 0.82 HPGD (0.77) MAPTHPGDALDH1A1CYP1A2CYP2C9
SCHEMBL20569921 0.79 HPGD (0.51) MAPTHPGDALDH1A1CYP1A2CYP2C9
SCHEMBL20569911 0.76 HPGD (0.50) MAPTHPGDALDH1A1CYP1A2CYP2C9
SCHEMBL20571335 0.75 CYP2C9 (0.55) MAPTHPGDALDH1A1CYP1A2CYP2C9
SCHEMBL20571130 0.75 KMT2A (0.68) MAPTHPGDALDH1A1CYP2A6MEN1
SCHEMBL20570664 0.75 HPGD (0.51) MAPTHPGDALDH1A1CYP1A2CYP2C9
SCHEMBL20303285 0.72 MAPT (1.00) MAPTHPGDALDH1A1KMT2AKDM4C
SCHEMBL30004904 0.72 MAPT (1.00) MAPTHPGDALDH1A1KMT2AKDM4C
SCHEMBL20570670 0.71 HPGD (0.79) HPGDALDH1A1CYP1A2CYP2C9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304597-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-10-02 US disclosed
US-20240043440-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-02-08 US disclosed
US-20210317132-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-14 US disclosed
US-20210317132-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-14 US disclosed
CN-111132982-A Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2020-05-08 CN disclosed
EP-3630773-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY Case Western Reserve University (US) 2020-04-08 EP disclosed
WO-2018218251-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304597-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS MAPT 4066/4885HPGD 1/4885ALDH1A1 126/4885
US-20210317132-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS MAPT 4066/4885HPGD 1/4885ALDH1A1 126/4885
US-20240043440-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS MAPT 4066/4885HPGD 1/4885ALDH1A1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.